Evidence for Platelet αIIbβ3 Activation despite Elevated Cytosolic cAMP

Summary

Cyclic nucleotides, such as cAMP, are known to inhibit the multistep cascade that results in platelet aggregation. In the present study we provide evidence that it is possible to bypass cAMP inhibitory effect on fibrinogen binding site exposure induced by the thromboxane A2 synthetic analogue U46619, the snake venom toxin convulxin, or by the direct PKC activator OAG, by concomitantly activating a G_i-coupled receptor by means of epinephrine or by inducing cytosolic calcium influx by means of ionomycin. In fact, in our study we demonstrate that, in iloprost-treated platelets, the inhibition of both platelet aggregation and fibrinogen binding was overcome by adding epinephrine or ionomycin. To further confirm this, we used the cAMP analogue dibutyryl cAMP and we obtained platelet aggregation in response to U46619, convulxin or OAG plus epinephrine. Moreover, a complete inhibition of platelet aggregation in the presence of high concentrations of cAMP was observed only in the case of U46619, while a small percentage of aggregation persisted when convulxin or OAG were used, due to the small amount of ADP that both convulxin and OAG are able to release.

Since PKC inhibition didn’t allow platelet aggregation to occur in response to the concomitant activation of U46619 or convulxin, plus epinephrine or ionomycin, we can conclude that cAMP-induced inhibition of aggregation can be counteracted by the simultaneous activation of PKC in the presence of an activated G_i-coupled receptor or of an induced calcium influx.

Keywords

Platelet aggregation - cAMP - PKC - PLC - G-protein

• References

• 1 Krishnamurthi S, Westwick J, Kakkar VV. Regulation of human platelet activation – analysis of cyclooxygenase and cyclic AMP-dependent pathways. Biochem Pharmacol 1984; 33: 3025-35.
• 2 Sage SO, Rink TJ. Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets. FEBS Lett 1985; 188: 135-40.
• 3 Bushfield M, McNicol A, MacIntyre DE. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. Biochem J 1985; 232: 267-71.
• 4 Watson SP, McConnell RT, Lapetina EG. The rapid formation of inositol phosphates in human platelets by thrombin is inhibited by prostacyclin. J Biol Chem 1984; 259: 13199-203.
• 5 Waldmann R, Walter U. Cyclic nucleotide-elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade. Eur J. Pharmacol 1989; 159: 317-20.
• 6 Siess W, Lapetina EG. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. Biochem J 1990; 271: 815-9.
• 7 Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature, 1980; 283: 195-7.
• 8 van Willigen G, Akkerman J-WN.. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glyco-protein IIb/IIIa complex of human platelets. Biochem J 1991; 273: 115-20.
• 9 Walter U, Eigenthaler M, Geiger J, Reinhard M. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Adv Exp Med Biol 1993; 344: 237-49.
• 10 Horstrup K, Jablonka B, Hönig-Liedle P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilators-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J. Biochem, 1994; 225: 21-7.
• 11 Shattil SJ. Regulation of platelet anchorage and signalling by integrin αIIbβ3. Thromb Haemost 1993; 70: 224-8.
• 12 Aszòdi A, Pfeifer A, Ahmad M, Glauner M, Zhou X-H, Ny L, Andersson K-E, Kehrel B, Offermanns S, Fässler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
• 13 Pulcinelli FM, Ashby B, Gazzaniga PP, Daniel JL. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS Lett 1995; 364: 87-90.
• 14 Pulcinelli FM, Pesciotti M, Pignatelli P, Riondino S, Gazzaniga PP. Concomitant activation of Gi and Gq protein-coupled receptors does not require an increase in cytosolic calcium for platelet aggregation. FEBS Lett 1998; 435: 115-8.
• 15 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci 1998; 95: 8070-4.
• 16 Nieuwland R, Wijburg OLC, Van Willigen G, Akkerman JWN. Alfa-2A adrenergic receptors activate protein kinase C in human platelets via a pertussis toxin-sensitive G-protein. FEBS Lett 1994; 339: 79-83.
• 17 Pulcinelli FM, Ciampa MT, Favilla M, Pignatelli P, Riondino S, Gazzaniga PP. Concomitant activation of G_i protein-coupled receptor and protein kinase C or phospholipase C is required for platelet aggregation. FEBS Lett, 1999; 460: 37-40.
• 18 Siess W, Lapetina EG. Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca²⁺ ionophore at steps distal to activation of protein kinase C and Ca²⁺ dependent protein kinases. Biochem J 1989; 258: 57-65.
• 19 Polgar J, Clemetson JM, Keherel BE, Wiedemann M, Magnenat EM, Wells TNC, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem 1997; 272: 13576-83.
• 20 Costa JJ, Murphy DL. Platelet 5-HT uptake and release stopped rapidly by formaldehyde. Nature 1975; 255: 405-7.
• 21 Zoccarato F, Ruzzene M, Cavallini L, Doni MG, Francesconi MA, Deana R, Alexandre A. Platelet responses promoted by the activation of protein kinase C or the increase of cytosolic Ca2+ are potentiated by adrenaline. Effects of cAMP and staurosporine. Biochem Biophys Acta 1991; 1092: 72-8.